ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2016
Nanoparticle formulations of cisplatin for cancer therapy.
Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hypocrellin-Mediated PDT: A Systematic Review of Its Efficacy, Applications, and Outcomes.International journal of molecular sciences · 2025Pooled it
- Article
- Molecular and Functional Interactions Between Cisplatin and Nicotinamide: A Combined Computational, Spectroscopic, and Biological Study.International journal of molecular sciences · 2026Article
- Assessment of pH-Responsive Ionisable Lipid Nanoparticles as Cisplatin Delivery Vehicles for Treating Cisplatin-Resistant Ovarian Cancer.Pharmaceutics · 2026Article
- Zinc Ferrite-Integrated Halloysite Nanotubes as a Platform for Folate-Mediated Targeted Cisplatin Delivery.International journal of molecular sciences · 2026Article
- Antiproliferative Effects of Cannabinoids and Cisplatin in Cervical Cancer Cells.Cancer reports (Hoboken, N.J.) · 2026Article
- Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems.Pharmaceutics · 2026Review
- Controlled Cisplatin Delivery Using pH-Sensitive PAA-Grafted Mesoporous Silica Nanoparticles.ACS omega · 2026Article
- Facile synthesis of platinated DNA nanoparticles with radiosensitizing potential.Beilstein journal of nanotechnology · 2026Article
- Cancer Therapy with Polymeric Nanocarriers and the Transition to Targeted Cancer Therapy: Advances and Future Directions.Pharmaceutical nanotechnology · 2026Review
- Smart polymeric nanoparticles for targeted delivery and microenvironment-responsive therapy in pancreatic cancer.Smart materials in medicine · 2025Article
- Biofabrication ofLife (Basel, Switzerland) · 2025Article
- Exploratory Gene Expression Profiling of Cisplatin-Induced Neurotoxicity in Rat Brain.International journal of molecular sciences · 2025Article
- Advancing cervical cancer treatment: integrating cannabinoids, combination therapies and nanotechnology.Journal of cancer research and clinical oncology · 2025Review
- Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies.Medical oncology (Northwood, London, England) · 2025Review
- Peptide-Based Nanoparticle for Tumor Therapy.Biomedicines · 2025Review
- Advances in Nanotechnology-Based Cisplatin Delivery for ORL Cancers: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Bioadhesive Eudragit RLPharmaceutics · 2025Article
- Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence.Frontiers in oncology · 2025Review
- Advances in nanocarrier-mediated delivery of chrysin: Enhancing solubility, bioavailability, and anticancer efficacy.BioImpacts : BI · 2025Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The genotoxic agent cisplatin, used alone or in combination with radiation and/or other chemotherapeutic agents, is an important first-line chemotherapy for a broad range of cancers. The clinical utility of cisplatin is limited both by intrinsic and acquired resistance and dose-limiting normal tissue toxicity. That cisplatin shows little selectivity for tumor versus normal tissue may be a critical factor limiting its value. To overcome the low therapeutic ratio of the free drug, macromolecular, liposomal, and nanoparticle drug delivery systems have been explored toward leveraging the enhanced permeability and retention effect and promoting delivery of cisplatin to tumors. Here, we survey recent advances in nanoparticle formulations of cisplatin, focusing on agents that show promise in preclinical or clinical settings. WIREs Nanomed Nanobiotechnol 2016, 8:776-791. doi: 10.1002/wnan.1390 For further resources related to this article, please visit the WIREs website.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.